[1] SUN H Y, SINGH N. Mucormycosis: its contemporary face and management strategies[J]. Lancet Infect Dis, 2011, 11(4): 301-311. [2] CORNELY O A, ALASTRUEY-IZQUIERDO A, ARENZ D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium[J]. Lancet Infect Dis, 2019, 19(12):e405-e421. [3] JEONG W, KEIGHLEY C, WOLFE R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports[J]. Clin Microbiol Infect, 2019,25(1):26-34. [4] WANG X, WANG A, WANG X, et al. Cutaneous mucormycosis caused by Mucor irregularis in a patient with CARD9 deficiency[J]. Br J Dermatol, 2019, 180(1): 213-214. [5] SKIADA A, RIGOPOULOS D, LARIOS G, et al. Global epidemiology of cutaneous zygomycosis[J]. Clin Dermatol, 2012, 30(6): 628-632. [6] LU X L, NAJAFZADEH M J, Dolatabadi S, et al. Taxonomy and epidemiology of Mucor irregularis, agent of chronic cutaneous mucormycosis[J]. Persoonia, 2013, 30: 48-56. DOI:10.3767/003158513X665539. [7] 夏志宽,刘畅,丛林等. 不规则毛霉感染引起的皮肤毛霉病20例回顾性分析[J]. 实用皮肤病学杂志, 2014, 7(3):161-165. [8] ZHANG S, LI R, YU J. Drug combinations against Mucor irregularis in vitro[J]. Antimicrob Agents Chemother, 2013, 57(7): 3395-3397. [9] 吕红莉, 李澄, 李燕,等. 中国原发性皮肤毛霉病32例回顾性分析[J]. 中国真菌学杂志, 2016, 11(2):103-107. [10] CARVER P L. The battle for iron between humans and microbes[J]. Curr Med Chem, 2018, 25(1): 85-96. [11] SPELLBERG B, IBRAHIM A S, CHIN-HONG P V, et al. The deferasirox-amBisome therapy for mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial[J]. J Antimicrob Chemother, 2012, 67(3): 715-722. |